As of Jul 25, 2024, the NBIX stock has a PE ratio of 38.75. The calculation is based on the latest EPS of $3.77 and the stock price of $146.1 per share. A decrease of 21% has been observed in the PE ratio compared to its average of 49.2 of the last four quarters.
The mean historical PE ratio of Neurocrine Biosciences over the last six years is 203.02. The current 38.75 P/E ratio is 81% lower than the historical average. Looking back at the last six years, NBIX's PE ratio peaked in the Sep 2018 quarter at 1,229.5, with a price of $122.95 and an EPS of $0.1. The Sep 2021 quarter marked the lowest point at 20.11, with a price of $95.91 and an EPS of $4.77.
Maximum annual increase: 309.73% in 2021
Maximum annual decrease: -91.86% in 2020
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 51.47 | -30.62% |
| 2022 | 74.19 | -17.24% |
| 2021 | 89.65 | 309.73% |
| 2020 | 21.88 | -91.86% |
| 2019 | 268.73 | -13.45% |
| 2018 | 310.48 | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
NBIX's current PE ratio is lower than its 3, 5 and 10-year averages.
In comparison to its peers LLY and ABBV, NBIX's PE ratio is lower, but it is higher than RPRX's and ANIP's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| RPRX Royalty Pharma plc | 16.09 | $17.21B |
| NBIX Neurocrine Biosciences Inc | 38.92 | $14.77B |
| ANIP Ani Pharmaceuticals Inc | 39.03 | $1.33B |
| ABBV AbbVie Inc | 54.94 | $326.97B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| RGEN Repligen Corp | 503.36 | $7.88B |
| PFE Pfizer Inc | N/A | $174.36B |
| PTN Palatin Technologies Inc | N/A | $27.43M |
| CASI CASI Pharmaceuticals Inc | N/A | $88.23M |
The price to earnings ratio for NBIX stock is 38.75 as of Jul 25, 2024.
Over the last 3 years, the average price to earnings ratio for NBIX stock is 143.57.
Over the last 5 years, the average price to earnings ratio for NBIX stock is 131.81.
The highest quarterly PE ratio in the last six years has been 1,229.5 and it was in the Sep 2018 quarter.
NBIX's current price to earnings ratio is 81% below its 6-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the EPS for the last 12 months. As of today (Jul 25, 2024), Neurocrine Biosciences's share price is $146.1. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $3.77. Therefore, Neurocrine Biosciences's PE ratio for today is 38.75. PE RATIO(38.75) = STOCK PRICE($146.1) / TTM EPS($3.77)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.